Pervasive Commodities Ltd
517172Pervasive Commodities Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.
Biggest watch item: margins are the best this company has ever printed — every ratio flatters at record profitability, so the whole story leans on margins holding.
The price is in a confirmed uptrend (18 weeks in). Underneath, the last four quarters read deteriorating — profit −90.0% year on year, and −11,813% of the last 3 years' profit arrived as cash. What settles it: the next one or two quarters of delivery.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Pervasive Commodities Ltd trades at ₹11.2, in a confirmed uptrend and 18 weeks into that stage. That is +184.3% against its own 200-day average. It sits at 100% of a 52-week range of ₹3 to ₹11. On relative strength it has no relative-strength read yet.
Today the stock is in a confirmed uptrend — week 18 of stage 2, confirmed. At ₹11.2 it trades +184.3% versus its 200-day average and sits at 100% of its 52-week range (₹3–₹11).
Against the market, two honest reads. Cumulative: over the last 4 months the stock moved +256% while the NIFTY 500 moved −2% — ahead of the index over the full window. Recent form: no trailing-13-week read yet — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Pervasive Commodities Ltd trades at 12.0× P/E, against too little history to rank. Its long-run median P/E is 12.0×. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 12.0× is against too little history to rank, against a long-run median of 12.0×. This is a comparison against the stock's own history — not a claim about what it is worth.
Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Pervasive Commodities Ltd reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 8 quarters across 2 curves, on partial evidence.
Why it matters: with too little history, an honest page says so instead of guessing a trajectory.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +42.3% | — | +66.0% | +62.3% |
4-Factor Sector Score
51.0/100 — rank 19 of 58 in Trading · 52% evidence confidence
Pervasive Commodities Ltd scores 51.0 out of 100 against the 58 companies it is compared with in Trading, ranking 19. Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
The four contributions add to the total exactly: 16.6 + 14.4 + 10 + 10 = 51. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Pervasive Commodities Ltd reported ₹0.5 Cr of revenue in the Jun 26 quarter, −86.6% year on year. Over 10 years it has compounded at 62.3% a year. The last full year, FY26, came in at ₹43.1 Cr. The last four reported quarters add to ₹39.9 Cr.
FY26 revenue came in at ₹43.1 Cr (+42.3% on the year), capping 10 years at 62.3% compound. The latest quarter (Jun 26) printed ₹0.5 Cr, −86.6% year on year.
Pace check: the last four quarters averaged +32.0% growth against the decade's 62.3% — the current year is running slower than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +25.6% over the last 4 quarters against +312.9%/yr over the last 8 — rolling over.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Pervasive Commodities Ltd's operating margin is −10.2% in the Jun 26 quarter, −6.1 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across 10 fiscal years the operating margin has ranged −112.5% to 37.2%. The current quarter sits inside that band.
The latest quarter's operating margin is −10.2%, −6.1 pp against the same quarter a year ago. Across 10 fiscal years the operating margin has ranged −112.5%–37.2%, and FY26's 37.2% is the top of that band — a record year.
🚨 Why the margin moved: operating margin went −6.1 pp year on year while gross margin went +32.3 pp — the loss came mostly from the gross line: input costs and pricing.
Worth repeating from the valuation section: cheap against its own history on record margins is not the same thing as cheap — a record margin flatters every ratio built on top of it.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Pervasive Commodities Ltd earned ₹0.0 Cr of net profit in the Jun 26 quarter, −90.0% year on year. The full FY26 year was a loss of ₹0.04 Cr. That is 2.0% of the quarter's revenue. The same quarter a year earlier earned ₹0.1 Cr. 3 of the last 12 reported quarters were loss-making.
Jun 26 profit was ₹0.0 Cr, −90.0% year on year. On the full year, FY26 printed ₹−0.0 Cr (−144.4%).
🚨 Why profit moved: revenue contributed −86.6% and the margin −6.1 pp — the quarter was revenue-led despite a thinner margin.
Pace comparison, last four quarters: profit −2,189.2% vs revenue +32.0%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years −11,813% of Pervasive Commodities Ltd's reported profit arrived as operating cash — a gap worth watching. In FY26 that was ₹−37.2 Cr of operating cash against ₹−0.0 Cr of profit. After ₹0.0 Cr of capital spending, ₹−37.0 Cr was left as free cash.
FY26: operating cash of ₹−37.2 Cr against reported profit of ₹−0.0 Cr, leaving free cash of ₹−37.0 Cr after ₹0.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is −11,813% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
🚨 Why conversion sits at −11,813%: the cash cycle stretched 696 days between FY19 and FY26 — more of each rupee of profit waits inside the cycle before arriving. Less than 70% of profit arriving as cash is the thing to watch on this page.
Router verdict: conversion is below par and the cash cycle has stretched 696 days — the next section's job is to find where the cash is stuck.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Pervasive Commodities Ltd's cash conversion cycle runs 696 days in FY26, up from 0 days in FY19. Capital spending ran ₹0.0 Cr over the last 3 years. At FY26 sales of ₹43.1 Cr each day of that cycle holds about ₹0.1 Cr, so roughly ₹82.0 Cr sits inside the business at any moment.
FY26: debtors at 311 days, inventory at 593 days — roughly 19.5 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 696 days, looser than FY19's 0.
The full loop: cash goes out to suppliers and production on day 0; stock waits 593 days to sell; customers pay about 311 days after that; and suppliers themselves are paid at 208 days — netting out to the 696-day cycle.
In money terms: at FY26 sales of ₹43.1 Cr, each day of the cycle holds about ₹0.1 Cr — so the 696-day loop keeps roughly ₹82.0 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹0.0 Cr over the last 3 fiscal years. Capital work-in-progress stands at ₹0.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the working-capital loop is the cash sink the router flagged — watch the cycle, not the P&L.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Pervasive Commodities Ltd earns a ROCE of 22% in FY26. That is up from a trough of −84% in FY15. A return-on-invested-capital spread against the cost of capital is not computable from what is held here. The wiring behind it is −0.1% net margin on 0.41× asset turns.
FY26 ROCE is 22%, recovered from a FY15 trough of −84% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY26): −0.1% net margin × 0.41× asset turns × 1.17× balance-sheet leverage ≈ 0.0% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.
Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.
Pervasive Commodities Ltd carries ₹0.3 Cr of borrowings against ₹90.0 Cr of equity in FY26, a debt-to-equity of 0.00. Operating profit covers the interest bill north of 100×. Over 5 years borrowings went from ₹0.0 Cr to ₹0.3 Cr. Capital spending ran ₹0.0 Cr across the last 3 of those years.
FY26: borrowings of ₹0.3 Cr against equity of ₹90.0 Cr — a debt-to-equity of 0.00. Operating profit covers the interest bill north of 100×. Over 5 years borrowings went from ₹0.0 Cr to ₹0.3 Cr while capital spending ran ₹0.0 Cr in just the last 3 — part of the build-out is riding on borrowed money.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Promoters cut 57.3 points of Pervasive Commodities Ltd over 8 quarters, the biggest move on the register. That takes promoters to 0.1% of the company. Domestic institutions moved −9.1 points over the same window, to 0.0%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Promoters: −57.3 points over 8 quarters to 0.1%; Domestic institutions: −9.1 points over 8 quarters to 0.0%. Note the structure: promoters hold under 20% — this is a widely-held company where institutions, not a family, set the direction.
🚨 Why the register moved: promoters drove it (−57.3 points), alongside domestic institutions (−9.1 points) — distribution into the market’s bid.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Pervasive Commodities Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Nupur Recyclers LtdNRL | 67.5/100Favorable setup87% evidence | LEADER | 22.2/35 Revenue 40.6% · PAT 29.8% · OPM change 3.6 pp 95% evidence | 16.6/25 ROCE 15.1% · OPM 11.6% 95% evidence | 8.8/20 P/E 63.8× · PEG — 50% evidence | 19.9/20 RS sector 91.7% · RS bench 122% · 1Y 108.2%12 of 12 weeks ahead 100% evidence |
| Exact sum: 22.2 + 16.6 + 8.8 + 19.9 = 67.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 2Magnus Steel & Infra Ltd517320 | 67.2/100Thin evidence · provisional56% evidence | 27.5/35 Revenue 100% · PAT 100% · OPM change 1.6 pp 83% evidence | 18.5/25 ROCE 171% · OPM 21.3% 76% evidence | 9.2/20 P/E 92.5× · PEG — 15% evidence | 12.0/20 RS sector — · RS bench 46.1% · 1Y 1238.7%11 of 12 weeks ahead to 2026-06-28 25% evidence | |
| Exact sum: 27.5 + 18.5 + 9.2 + 12 = 67.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 3Vision Infra Equipment Solutions LtdVIESL | 66.5/100Thin evidence · provisional56% evidence | BREAKING OUT | 18.9/35 Revenue — · PAT — · OPM change 0 pp 26% evidence | 19.9/25 ROCE 22.6% · OPM 26% 95% evidence | 10.9/20 P/E 13.8× · PEG — 15% evidence | 16.8/20 RS sector 14.5% · RS bench 34.1% · 1Y 52.1%9 of 12 weeks ahead 100% evidence |
| Exact sum: 18.9 + 19.9 + 10.9 + 16.8 = 66.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 4Rashi Peripherals LtdRPTECH | 63.3/100Mixed-positive evidence75% evidence | LEADER | 24.3/35 Revenue 40.4% · PAT 50.2% · OPM change -0.3 pp 95% evidence | 14.7/25 ROCE 17% · OPM 3% 76% evidence | 10.6/20 P/E 18.2× · PEG — 15% evidence | 13.7/20 RS sector 55.9% · RS bench 78.7% · 1Y 180.7%12 of 12 weeks ahead 100% evidence |
| Exact sum: 24.3 + 14.7 + 10.6 + 13.7 = 63.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Shankara Buildpro LtdBUILDPRO | 62.8/100Mixed-positive evidence63% evidence | BREAKING OUT | 25.1/35 Revenue 26.3% · PAT 41.9% · OPM change -0.2 pp 100% evidence | 17.4/25 ROCE 39% · OPM 3.2% 100% evidence | 10.3/20 P/E 23.1× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —10 of 12 weeks ahead 0% evidence |
| Exact sum: 25.1 + 17.4 + 10.3 + 10 = 62.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Pramara Promotions LtdPRAMARA | 61.7/100Mixed-positive evidence69% evidence | 22.3/35 Revenue 72.7% · PAT 100% · OPM change 1 pp 59% evidence | 14.3/25 ROCE 15% · OPM 14.6% 95% evidence | 14.4/20 P/E 14.2× · PEG — 50% evidence | 10.7/20 RS sector 7.9% · RS bench -60.1% · 1Y -62.9%10 of 12 weeks ahead 70% evidence | |
| Exact sum: 22.3 + 14.3 + 14.4 + 10.7 = 61.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Tembo Global Industries LtdTEMBO | 61.4/100Mixed-positive evidence80% evidence | TURNING | 21.7/35 Revenue 34% · PAT 55.7% · OPM change 5 pp 95% evidence | 18.5/25 ROCE 22.8% · OPM 16% 95% evidence | 11.3/20 P/E 10.6× · PEG — 15% evidence | 9.9/20 RS sector -15.7% · RS bench 0.5% · 1Y -4.7%1 of 12 weeks ahead 100% evidence |
| Exact sum: 21.7 + 18.5 + 11.3 + 9.9 = 61.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Arisinfra Solutions LtdARIS | 58.5/100Mixed-positive evidence65% evidence | BREAKING OUT | 21.7/35 Revenue 45.3% · PAT 100% · OPM change 2 pp 95% evidence | 15.1/25 ROCE 15.6% · OPM 11% 95% evidence | 10.6/20 P/E 17.4× · PEG — 15% evidence | 11.1/20 RS sector — · RS bench 12.5% · 1Y -12.1%6 of 11 weeks ahead 25% evidence |
| Exact sum: 21.7 + 15.1 + 10.6 + 11.1 = 58.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9Ivalue Infosolutions LtdIVALUE | 58.5/100Mixed-positive evidence65% evidence | ASLEEP | 20.2/35 Revenue 5.4% · PAT 22.1% · OPM change 5.6 pp 95% evidence | 18.6/25 ROCE 25.4% · OPM 10% 95% evidence | 11.2/20 P/E 11.1× · PEG — 15% evidence | 8.5/20 RS sector — · RS bench -11.3% · 1Y -18.7%5 of 11 weeks ahead 25% evidence |
| Exact sum: 20.2 + 18.6 + 11.2 + 8.5 = 58.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10Mangalam Global Enterprise LtdMGEL | 58.4/100Mixed-positive evidence80% evidence | 25.1/35 Revenue 41.4% · PAT 100% · OPM change 0.5 pp 95% evidence | 15.9/25 ROCE 17% · OPM 1.9% 95% evidence | 11.1/20 P/E 13× · PEG — 15% evidence | 6.3/20 RS sector -15% · RS bench -0.2% · 1Y -6.2%4 of 5 weeks ahead to 2026-08-09 100% evidence | |
| Exact sum: 25.1 + 15.9 + 11.1 + 6.3 = 58.4 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -15% and the one-year return is -6.2%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 11Euro Pratik Sales LtdEUROPRATIK | 57.7/100Mixed-positive evidence78% evidence | ASLEEP | 14.9/35 Revenue 23.9% · PAT 29% · OPM change -8 pp 100% evidence | 19.4/25 ROCE 36.9% · OPM 26% 100% evidence | 15.2/20 P/E 25.3× · PEG 0.62 65% evidence | 8.2/20 RS sector — · RS bench -20.6% · 1Y -9.2%5 of 11 weeks ahead 25% evidence |
| Exact sum: 14.9 + 19.4 + 15.2 + 8.2 = 57.7 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 12Singer India LtdSINGERIND | 57.3/100Thin evidence · provisional52% evidence | 26.1/35 Revenue 43.5% · PAT 100% · OPM change 6.5 pp 71% evidence | 10.2/25 ROCE 10.9% · OPM 2.5% 76% evidence | 10.1/20 P/E 25.9× · PEG — 15% evidence | 10.9/20 RS sector — · RS bench 9.7% · 1Y — 25% evidence | |
| Exact sum: 26.1 + 10.2 + 10.1 + 10.9 = 57.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 13Aayush Art and Bullion Ltd540718 | 56.7/100Thin evidence · provisional54% evidence | BREAKING OUT | 21.0/35 Revenue 100% · PAT — · OPM change 1.6 pp 35% evidence | 13.1/25 ROCE 18.9% · OPM 6% 76% evidence | 8.8/20 P/E 252× · PEG — 15% evidence | 13.8/20 RS sector -0.7% · RS bench 17.3% · 1Y 35.1%5 of 12 weeks ahead 100% evidence |
| Exact sum: 21 + 13.1 + 8.8 + 13.8 = 56.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 14Sudarshan Pharma Industries Ltd543828 | 56.4/100Mixed-positive evidence82% evidence | FADING | 20.5/35 Revenue 32.9% · PAT 24.3% · OPM change 1.5 pp 95% evidence | 13.7/25 ROCE 15.1% · OPM 9.1% 76% evidence | 8.5/20 P/E 38.2× · PEG — 50% evidence | 13.7/20 RS sector 11.1% · RS bench 29.7% · 1Y 32.2%11 of 12 weeks ahead 100% evidence |
| Exact sum: 20.5 + 13.7 + 8.5 + 13.7 = 56.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15Lloyds Enterprises LtdLLOYDSENT | 55.0/100Mixed-positive evidence75% evidence | TURNING | 18.0/35 Revenue 33% · PAT -21.4% · OPM change 9 pp 95% evidence | 11.2/25 ROCE 3.7% · OPM 16% 76% evidence | 9.1/20 P/E 103× · PEG — 15% evidence | 16.7/20 RS sector 6.1% · RS bench 24.9% · 1Y 19.1%9 of 12 weeks ahead 100% evidence |
| Exact sum: 18 + 11.2 + 9.1 + 16.7 = 55 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16Onix Solar Energy LtdONIXSOLAR | 54.8/100Mixed-positive evidence69% evidence | 20.6/35 Revenue 26.2% · PAT 100% · OPM change 23 pp 95% evidence | 11.7/25 ROCE 11.3% · OPM 30% 76% evidence | 10.1/20 P/E 27.5× · PEG — 15% evidence | 12.4/20 RS sector 68.4% · RS bench -25.8% · 1Y 19.8%12 of 12 weeks ahead 70% evidence | |
| Exact sum: 20.6 + 11.7 + 10.1 + 12.4 = 54.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17Patel Retail LtdPATELRMART | 53.2/100Mixed-positive evidence65% evidence | FADING | 17.9/35 Revenue 42.3% · PAT 59.7% · OPM change -2.2 pp 95% evidence | 14.3/25 ROCE 15.3% · OPM 6.1% 95% evidence | 10.7/20 P/E 16.6× · PEG — 15% evidence | 10.3/20 RS sector — · RS bench 2.1% · 1Y -12.3%4 of 11 weeks ahead 25% evidence |
| Exact sum: 17.9 + 14.3 + 10.7 + 10.3 = 53.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18Prostarm Info Systems LtdPROSTARM | 51.8/100Mixed-positive evidence65% evidence | TURNING | 16.6/35 Revenue 30.5% · PAT 19.1% · OPM change 1.4 pp 95% evidence | 16.0/25 ROCE 18% · OPM 8.5% 95% evidence | 10.4/20 P/E 22.7× · PEG — 15% evidence | 8.8/20 RS sector — · RS bench -4.7% · 1Y -31.9%0 of 11 weeks ahead 25% evidence |
| Exact sum: 16.6 + 16 + 10.4 + 8.8 = 51.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 19Pervasive Commodities Ltdthis page517172 | 51.0/100Thin evidence · provisional52% evidence | TURNING | 16.6/35 Revenue 25.6% · PAT -8.3% · OPM change -6.1 pp 95% evidence | 14.4/25 ROCE 22.1% · OPM -10.2% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 10.0/20 RS sector — · RS bench — · 1Y —2 of 2 weeks ahead 0% evidence |
| Exact sum: 16.6 + 14.4 + 10 + 10 = 51 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 20Fabtech Technologies LtdFABTECH | 50.9/100Thin evidence · provisional52% evidence | ASLEEP | 17.5/35 Revenue 14.2% · PAT 41% · OPM change 14.8 pp 71% evidence | 12.4/25 ROCE 13.6% · OPM 5.7% 95% evidence | 11.0/20 P/E 13.3× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y -25.2%0 of 11 weeks ahead 0% evidence |
| Exact sum: 17.5 + 12.4 + 11 + 10 = 50.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 21BMW Ventures LtdBMW | 49.8/100Thin evidence · provisional55% evidence | 16.7/35 Revenue 18.5% · PAT 24.2% · OPM change -0.6 pp 95% evidence | 12.0/25 ROCE 12% · OPM 3.4% 76% evidence | 11.1/20 P/E 12.2× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y -18.7%0 of 10 weeks ahead to 2026-08-23 0% evidence | |
| Exact sum: 16.7 + 12 + 11.1 + 10 = 49.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 22Yogi LtdYOGI | 48.8/100Thin evidence · provisional58% evidence | 20.1/35 Revenue 97.5% · PAT 68.1% · OPM change -5.9 pp 62% evidence | 10.1/25 ROCE 12.8% · OPM 2.6% 76% evidence | 9.4/20 P/E 55.5× · PEG — 15% evidence | 9.2/20 RS sector -6.5% · RS bench 2.3% · 1Y -4.3%2 of 12 weeks ahead 70% evidence | |
| Exact sum: 20.1 + 10.1 + 9.4 + 9.2 = 48.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 23Bizotic Commercial Ltd543926 | 48.6/100Thin evidence · provisional58% evidence | BASING | 19.7/35 Revenue — · PAT — · OPM change 0 pp 26% evidence | 18.7/25 ROCE 26.8% · OPM 8% 76% evidence | 9.3/20 P/E 36.6× · PEG — 50% evidence | 0.9/20 RS sector -85.7% · RS bench -11.9% · 1Y -76.9%0 of 12 weeks ahead 100% evidence |
| Exact sum: 19.7 + 18.7 + 9.3 + 0.9 = 48.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 24SG Mart LtdSGMART | 48.3/100Mixed-negative evidence93% evidence | LEADER | 13.7/35 Revenue 10.4% · PAT 14.7% · OPM change 1.4 pp 100% evidence | 8.4/25 ROCE 10.2% · OPM 4.5% 100% evidence | 8.2/20 P/E 74× · PEG 1.92 65% evidence | 18.0/20 RS sector 25.9% · RS bench 45.7% · 1Y 91.5%12 of 12 weeks ahead 100% evidence |
| Exact sum: 13.7 + 8.4 + 8.2 + 18 = 48.3 · Decision use: Price leads the evidence: RS versus the benchmark is 45.7%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 25Shiv Aum Steels LtdSHIVAUM | 47.6/100Thin evidence · provisional55% evidence | BREAKING OUT | 16.8/35 Revenue — · PAT — · OPM change 1.3 pp 45% evidence | 11.4/25 ROCE 8% · OPM 4.7% 95% evidence | 7.3/20 P/E 77.5× · PEG — 50% evidence | 12.1/20 RS sector — · RS bench 49.9% · 1Y —8 of 8 weeks ahead 25% evidence |
| Exact sum: 16.8 + 11.4 + 7.3 + 12.1 = 47.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 26State Trading Corporation of India LtdSTCINDIA | 46.7/100Thin evidence · provisional57% evidence | ASLEEP | 22.8/35 Revenue — · PAT 100% · OPM change — 57% evidence | 7.6/25 ROCE 7.6% · OPM — 80% evidence | 10.8/20 P/E 15.6× · PEG — 15% evidence | 5.5/20 RS sector -28.7% · RS bench -6.8% · 1Y -11.5%1 of 12 weeks ahead 70% evidence |
| Exact sum: 22.8 + 7.6 + 10.8 + 5.5 = 46.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 27Dhunseri Ventures LtdDVL | 46.6/100Mixed-negative evidence87% evidence | BREAKING OUT | 12.5/35 Revenue -20% · PAT 31.7% · OPM change -12 pp 95% evidence | 9.4/25 ROCE 6.7% · OPM 39% 95% evidence | 11.9/20 P/E 5.3× · PEG — 50% evidence | 12.8/20 RS sector -6.5% · RS bench 11.7% · 1Y -19.2%7 of 12 weeks ahead 100% evidence |
| Exact sum: 12.5 + 9.4 + 11.9 + 12.8 = 46.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 28MMTC LtdMMTC | 42.3/100Mixed-negative evidence96% evidence | ASLEEP | 15.0/35 Revenue 0% · PAT 100% · OPM change -1270 pp 100% evidence | 7.8/25 ROCE 8.7% · OPM — 84% evidence | 15.6/20 P/E 43.5× · PEG 0.92 100% evidence | 3.9/20 RS sector -21% · RS bench -6.1% · 1Y -13.4%1 of 12 weeks ahead 100% evidence |
| Exact sum: 15 + 7.8 + 15.6 + 3.9 = 42.3 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 29Hexa Tradex LtdHEXATRADEX | 41.7/100Mixed-negative evidence65% evidence | TURNING | 17.0/35 Revenue 0.4% · PAT 70.3% · OPM change 13.6 pp 71% evidence | 6.2/25 ROCE -0.1% · OPM — 80% evidence | 10.0/20 P/E — · PEG — 0% evidence | 8.5/20 RS sector -17.1% · RS bench -1.3% · 1Y -11.9%0 of 12 weeks ahead 100% evidence |
| Exact sum: 17 + 6.2 + 10 + 8.5 = 41.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 30Cropster Agro Ltd523105 | 41.1/100Mixed-negative evidence69% evidence | ASLEEP | 15.3/35 Revenue 28.4% · PAT 6.5% · OPM change 1.7 pp 95% evidence | 11.7/25 ROCE 12.4% · OPM 9.8% 76% evidence | 10.8/20 P/E 15.6× · PEG — 15% evidence | 3.3/20 RS sector -72.7% · RS bench -73.3% · 1Y -86.8%0 of 4 weeks ahead 70% evidence |
| Exact sum: 15.3 + 11.7 + 10.8 + 3.3 = 41.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 31Adani Enterprises LtdADANIENT | 41.0/100Mixed-negative evidence93% evidence | ASLEEP | 14.1/35 Revenue 18.1% · PAT 4.2% · OPM change 0 pp 100% evidence | 8.3/25 ROCE 5.8% · OPM 15% 100% evidence | 7.6/20 P/E 166× · PEG 1.96 65% evidence | 11.0/20 RS sector 1% · RS bench 18.4% · 1Y 19.2%8 of 12 weeks ahead 100% evidence |
| Exact sum: 14.1 + 8.3 + 7.6 + 11 = 41 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 32RRP Semiconductor LtdRRP | 40.9/100Thin evidence · provisional54% evidence | 11.2/35 Revenue -80% · PAT -80% · OPM change 3.3 pp 71% evidence | 5.6/25 ROCE -32.7% · OPM — 61% evidence | 10.0/20 P/E — · PEG — 0% evidence | 14.1/20 RS sector 65.3% · RS bench 0.8% · 1Y 36.6%0 of 1 week ahead to 2026-08-23 70% evidence | |
| Exact sum: 11.2 + 5.6 + 10 + 14.1 = 40.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 33Le Merite Exports LtdLEMERITE | 40.1/100Thin evidence · provisional57% evidence | 18.0/35 Revenue — · PAT — · OPM change -15.5 pp 45% evidence | 6.8/25 ROCE 9.9% · OPM -10.7% 95% evidence | 9.1/20 P/E 94.5× · PEG — 15% evidence | 6.2/20 RS sector -9% · RS bench -68.5% · 1Y -94.7%0 of 2 weeks ahead 70% evidence | |
| Exact sum: 18 + 6.8 + 9.1 + 6.2 = 40.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 34Blue Pearl Agriventures LtdBPAGRI | 39.2/100Mixed-negative evidence69% evidence | 20.0/35 Revenue 19.3% · PAT 59.1% · OPM change 0.3 pp 95% evidence | 6.2/25 ROCE 2.2% · OPM 3.3% 76% evidence | 8.7/20 P/E 514× · PEG — 15% evidence | 4.3/20 RS sector -33.5% · RS bench -82.5% · 1Y -88.6%1 of 12 weeks ahead to 2026-08-23 70% evidence | |
| Exact sum: 20 + 6.2 + 8.7 + 4.3 = 39.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 35Riddhi Siddhi Gluco Biols Ltd524480 | 39.0/100Mixed-negative evidence82% evidence | FADING | 12.4/35 Revenue -38% · PAT 38.4% · OPM change -2.8 pp 95% evidence | 6.5/25 ROCE 2.7% · OPM -3% 76% evidence | 6.3/20 P/E 37.4× · PEG — 50% evidence | 13.8/20 RS sector 7.8% · RS bench 25.9% · 1Y 28.1%7 of 12 weeks ahead 100% evidence |
| Exact sum: 12.4 + 6.5 + 6.3 + 13.8 = 39 · Decision use: Price leads the evidence: RS versus the benchmark is 25.9%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 36Hardwyn India LtdHARDWYN | 38.7/100Mixed-negative evidence87% evidence | ASLEEP | 13.5/35 Revenue 2.6% · PAT -8.5% · OPM change -0.2 pp 95% evidence | 12.3/25 ROCE 4.8% · OPM 13% 95% evidence | 11.1/20 P/E 51.2× · PEG — 50% evidence | 1.8/20 RS sector -38.8% · RS bench -27.7% · 1Y -3.8%1 of 12 weeks ahead 100% evidence |
| Exact sum: 13.5 + 12.3 + 11.1 + 1.8 = 38.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 37Neueon Corporation LtdNEUEON | 37.6/100Thin evidence · provisional59% evidence | ASLEEP | 9.1/35 Revenue 17.8% · PAT -80% · OPM change -1039 pp 71% evidence | 3.9/25 ROCE -40.4% · OPM — 80% evidence | 10.0/20 P/E — · PEG — 0% evidence | 14.6/20 RS sector 12.7% · RS bench 16.3% · 1Y —0 of 12 weeks ahead 70% evidence |
| Exact sum: 9.1 + 3.9 + 10 + 14.6 = 37.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 38PTC India LtdPTC | 36.6/100Mixed-negative evidence82% evidence | BASING | 11.2/35 Revenue 13.3% · PAT -43.1% · OPM change -3.9 pp 95% evidence | 12.7/25 ROCE 13.4% · OPM 3.1% 76% evidence | 8.9/20 P/E 9× · PEG — 50% evidence | 3.8/20 RS sector -21.7% · RS bench -7.2% · 1Y -11.3%0 of 12 weeks ahead 100% evidence |
| Exact sum: 11.2 + 12.7 + 8.9 + 3.8 = 36.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 39Kothari Industrial Corporation LtdKOTIC | 34.3/100Adverse evidence63% evidence | BASING | 18.7/35 Revenue 75.9% · PAT -80% · OPM change -41.8 pp 71% evidence | 1.7/25 ROCE -28.9% · OPM -43% 95% evidence | 10.0/20 P/E — · PEG — 0% evidence | 3.9/20 RS sector -58.6% · RS bench -33.2% · 1Y -71.2%0 of 11 weeks ahead 70% evidence |
| Exact sum: 18.7 + 1.7 + 10 + 3.9 = 34.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 40BN Agrochem LtdBNAGROCHEM | 32.1/100Adverse evidence77% evidence | BASING | 12.8/35 Revenue 84.5% · PAT -61% · OPM change -9.4 pp 100% evidence | 4.2/25 ROCE 4.4% · OPM 2.3% 100% evidence | 9.0/20 P/E 119× · PEG — 15% evidence | 6.1/20 RS sector -16.7% · RS bench -26.3% · 1Y -40.5%4 of 12 weeks ahead 70% evidence |
| Exact sum: 12.8 + 4.2 + 9 + 6.1 = 32.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 41Shanti Overseas (India) LtdSHANTI | 32.0/100Thin evidence · provisional56% evidence | 11.3/35 Revenue -63.4% · PAT 100% · OPM change -200.5 pp 40% evidence | 4.7/25 ROCE -25.2% · OPM -216.5% 71% evidence | 12.4/20 P/E 3× · PEG — 50% evidence | 3.6/20 RS sector -60.4% · RS bench -49.7% · 1Y -45.6%0 of 12 weeks ahead to 2026-03-29 70% evidence | |
| Exact sum: 11.3 + 4.7 + 12.4 + 3.6 = 32 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 42Uniphos Enterprises LtdUNIENTER | 29.8/100Adverse evidence69% evidence | ASLEEP | 12.3/35 Revenue -77.1% · PAT 100% · OPM change -0.9 pp 71% evidence | 4.5/25 ROCE 0.8% · OPM — 80% evidence | 8.3/20 P/E 30.4× · PEG — 50% evidence | 4.7/20 RS sector -43.6% · RS bench -20.6% · 1Y -42.2%0 of 11 weeks ahead 70% evidence |
| Exact sum: 12.3 + 4.5 + 8.3 + 4.7 = 29.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 43Oswal Agro Mills LtdOSWALAGRO | 24.7/100Adverse evidence67% evidence | BASING | 2.9/35 Revenue -80% · PAT -80% · OPM change -21782.3 pp 95% evidence | 7.7/25 ROCE 2% · OPM — 80% evidence | 10.0/20 P/E — · PEG — 0% evidence | 4.1/20 RS sector -50.3% · RS bench -30.3% · 1Y -55.2%0 of 11 weeks ahead 70% evidence |
| Exact sum: 2.9 + 7.7 + 10 + 4.1 = 24.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 44Susan Electricals India Ltd544793 | 58.9/100Thin evidence · provisional31% evidence | 20.6/35 Revenue — · PAT — · OPM change 7.8 pp 26% evidence | 18.1/25 ROCE 37% · OPM 11.9% 76% evidence | 10.2/20 P/E 23.6× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y — 0% evidence | |
| Exact sum: 20.6 + 18.1 + 10.2 + 10 = 58.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 45Q-Line Biotech LtdQLINE | 57.7/100Thin evidence · provisional31% evidence | TURNING | 17.9/35 Revenue — · PAT — · OPM change 10 pp 13% evidence | 19.8/25 ROCE 22.5% · OPM 31% 95% evidence | 10.0/20 P/E 27.7× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —3 of 3 weeks ahead 0% evidence |
| Exact sum: 17.9 + 19.8 + 10 + 10 = 57.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 46DC Infotech & Communication LtdDCI | 57.5/100Thin evidence · provisional35% evidence | TURNING | 18.4/35 Revenue — · PAT — · OPM change 0.3 pp 24% evidence | 17.7/25 ROCE 22.9% · OPM 4.7% 76% evidence | 10.4/20 P/E 22.7× · PEG — 15% evidence | 11.0/20 RS sector — · RS bench 10.5% · 1Y —1 of 1 week ahead 25% evidence |
| Exact sum: 18.4 + 17.7 + 10.4 + 11 = 57.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 47Mardia Samyoung Capillary Tubes Company LtdMSCTC | 57.0/100Thin evidence · provisional32% evidence | 20.9/35 Revenue 100% · PAT 100% · OPM change — 29% evidence | 15.3/25 ROCE 22.6% · OPM 15.3% 57% evidence | 8.6/20 P/E 687× · PEG — 15% evidence | 12.2/20 RS sector — · RS bench 74.6% · 1Y 59.1%6 of 12 weeks ahead to 2026-03-08 25% evidence | |
| Exact sum: 20.9 + 15.3 + 8.6 + 12.2 = 57 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 48Proventus Agrocom LtdPROV | 56.5/100Thin evidence · provisional48% evidence | BREAKING OUT | 19.5/35 Revenue — · PAT — · OPM change 0.2 pp 26% evidence | 12.7/25 ROCE 11.5% · OPM 1.8% 95% evidence | 12.5/20 P/E 47.8× · PEG — 50% evidence | 11.8/20 RS sector — · RS bench 39.7% · 1Y —12 of 12 weeks ahead 25% evidence |
| Exact sum: 19.5 + 12.7 + 12.5 + 11.8 = 56.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 49SK Minerals & Additives Ltd544584 | 55.5/100Thin evidence · provisional36% evidence | BREAKING OUT | 16.5/35 Revenue — · PAT — · OPM change 1.3 pp 39% evidence | 19.1/25 ROCE 26.2% · OPM 10.7% 76% evidence | 9.9/20 P/E 27.9× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —5 of 6 weeks ahead 0% evidence |
| Exact sum: 16.5 + 19.1 + 9.9 + 10 = 55.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 50Arvaya Healthcare LtdARVAYA | 54.7/100Thin evidence · provisional19% evidence | 18.6/35 Revenue — · PAT — · OPM change 46.1 pp 10% evidence | 12.3/25 ROCE — · OPM 13% 30% evidence | 11.4/20 P/E 3.9× · PEG — 15% evidence | 12.4/20 RS sector — · RS bench 104.2% · 1Y — 25% evidence | |
| Exact sum: 18.6 + 12.3 + 11.4 + 12.4 = 54.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 51Monika Alcobev LtdMONIKA | 53.9/100Thin evidence · provisional22% evidence | 16.4/35 Revenue — · PAT — · OPM change -2 pp 15% evidence | 17.0/25 ROCE 21% · OPM 15% 57% evidence | 10.5/20 P/E 20.4× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y -19.3%0 of 12 weeks ahead to 2026-03-08 0% evidence | |
| Exact sum: 16.4 + 17 + 10.5 + 10 = 53.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 52Shah Foods Ltd519031 | 53.5/100Thin evidence · provisional18% evidence | BREAKING OUT | 17.1/35 Revenue — · PAT — · OPM change -10.7 pp 7% evidence | 15.3/25 ROCE — · OPM 18% 30% evidence | 8.9/20 P/E 246× · PEG — 15% evidence | 12.2/20 RS sector — · RS bench 75.6% · 1Y —6 of 6 weeks ahead 25% evidence |
| Exact sum: 17.1 + 15.3 + 8.9 + 12.2 = 53.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 53Manbro Industries Ltd512595 | 51.0/100Thin evidence · provisional22% evidence | 18.3/35 Revenue — · PAT — · OPM change 32.8 pp 5% evidence | 13.2/25 ROCE — · OPM 6.6% 23% evidence | 10.0/20 P/E — · PEG — 0% evidence | 9.5/20 RS sector -17.3% · RS bench 37.2% · 1Y 75.3%12 of 12 weeks ahead to 2026-05-03 70% evidence | |
| Exact sum: 18.3 + 13.2 + 10 + 9.5 = 51 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 54Satani Bearings Ltd505703 | 45.2/100Thin evidence · provisional38% evidence | TURNING | 20.5/35 Revenue — · PAT 100% · OPM change — 33% evidence | 4.7/25 ROCE 1% · OPM -3.7% 76% evidence | 8.6/20 P/E 5291× · PEG — 15% evidence | 11.4/20 RS sector — · RS bench 24.6% · 1Y 181.4%3 of 11 weeks ahead 25% evidence |
| Exact sum: 20.5 + 4.7 + 8.6 + 11.4 = 45.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 55Keto Motors Ltd537392 | 43.2/100Thin evidence · provisional38% evidence | BREAKING OUT | 16.2/35 Revenue — · PAT 100% · OPM change — 33% evidence | 6.0/25 ROCE -0.3% · OPM 10.7% 76% evidence | 8.5/20 P/E 7722× · PEG — 15% evidence | 12.5/20 RS sector — · RS bench 241.5% · 1Y —6 of 6 weeks ahead 25% evidence |
| Exact sum: 16.2 + 6 + 8.5 + 12.5 = 43.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 56A-1 LtdA1L | 41.0/100Thin evidence · provisional50% evidence | 16.1/35 Revenue 8.3% · PAT -30.6% · OPM change -0.9 pp 53% evidence | 10.7/25 ROCE 10.6% · OPM 2.9% 57% evidence | 8.7/20 P/E 383× · PEG — 15% evidence | 5.5/20 RS sector -24.5% · RS bench -16% · 1Y -10.6%6 of 12 weeks ahead to 2026-03-08 70% evidence | |
| Exact sum: 16.1 + 10.7 + 8.7 + 5.5 = 41 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 57Aerpace Industries Ltd534733 | 40.5/100Thin evidence · provisional32% evidence | 13.0/35 Revenue — · PAT -80% · OPM change — 33% evidence | 5.6/25 ROCE -21.5% · OPM — 61% evidence | 10.0/20 P/E — · PEG — 0% evidence | 11.9/20 RS sector — · RS bench 44% · 1Y — 25% evidence | |
| Exact sum: 13 + 5.6 + 10 + 11.9 = 40.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 58Prabhatam Infra Venture LtdPRABHATAM | 39.2/100Thin evidence · provisional22% evidence | 16.1/35 Revenue — · PAT -80% · OPM change — 8% evidence | 3.1/25 ROCE -97.1% · OPM -23.1% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 10.0/20 RS sector — · RS bench — · 1Y — 0% evidence | |
| Exact sum: 16.1 + 3.1 + 10 + 10 = 39.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Pervasive Commodities Ltd's share price today?
Pervasive Commodities Ltd trades at ₹11.2. The company is valued at ₹1,029 Cr. The stock sits at the very top of its 52-week range (₹3–₹11), +184.3% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 18 weeks in. — as of 25 September 2026.
What were Pervasive Commodities Ltd's latest quarterly results?
Pervasive Commodities Ltd reported revenue of ₹0.5 Cr and net profit of ₹0.0 Cr for the Jun 26 quarter. Revenue fell 86.6% and profit fell 90.0% year on year. Earnings per share were ₹0.00. The operating margin was −10.2%, 6.1 pp lower than a year earlier. — as of 25 September 2026.
What is Pervasive Commodities Ltd's revenue?
Pervasive Commodities Ltd reported revenue of ₹0.5 Cr in the Jun 26 quarter, −86.6% year on year. For the full FY26 fiscal year, revenue was ₹43.1 Cr (+42.3%). Over the last 10 years revenue compounded at 62.3% a year. — as of 25 September 2026.
What is Pervasive Commodities Ltd's profit?
Pervasive Commodities Ltd earned ₹0.0 Cr of net profit in the Jun 26 quarter, −90.0% year on year. Full-year FY26 profit was ₹−0.0 Cr. The operating margin ran −10.2% in the latest quarter. — as of 25 September 2026.
What is Pervasive Commodities Ltd's market cap?
Pervasive Commodities Ltd's market capitalisation is ₹1,029 Cr at a share price of ₹11.2. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 25 September 2026.
Does Pervasive Commodities Ltd pay a dividend?
Not in its latest year — Pervasive Commodities Ltd's dividend payout was 0% of profit in FY26. It did record a payout in 2 of its last 11 reported fiscal years, so there is a history but no current dividend. This page holds the payout ratio, not a per-share amount. — as of 25 September 2026.
Is Pervasive Commodities Ltd growing?
Not right now — Pervasive Commodities Ltd's latest numbers are shrinking: latest-quarter revenue −86.6% year on year, profit −90.0%, and the margin −6.1 pp at −10.2%. The earnings engine currently reads: deteriorating — as of 25 September 2026.
How is Pervasive Commodities Ltd performing?
Pervasive Commodities Ltd is in a confirmed uptrend, 18 weeks in. Its latest quarter's revenue fell 86.6% and profit fell 90.0% year on year. This describes what the data did, not a rating. — as of 25 September 2026.
Is Pervasive Commodities Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 18 of stage 2), trading +184.3% versus its 200-day average and at the very top of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 25 September 2026.
Will Pervasive Commodities Ltd's share price go up?
This page publishes no price forecast for Pervasive Commodities Ltd. What it measures instead: the share price is ₹11.2, the price is in a confirmed uptrend 18 weeks in. Direction is not something this site claims to know. — as of 25 September 2026.
Who owns Pervasive Commodities Ltd?
Promoters hold 0.1% of Pervasive Commodities Ltd, foreign institutions null%, domestic institutions 0.0% and the public 99.9% (latest quarter). The biggest move on the register over the last two years: Promoters cut 57.3 points over 8 quarters. — as of 25 September 2026.
Does Pervasive Commodities Ltd have too much debt?
No — Pervasive Commodities Ltd's debt-to-equity is 0.00, and operating profit covers the interest bill north of 100×. FY26 borrowings were ₹0.3 Cr against equity of ₹90.0 Cr. The returns on this page are earned, not borrowed — as of 25 September 2026.
What is Pervasive Commodities Ltd's capex?
Pervasive Commodities Ltd spent ₹0.0 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹0.0 Cr, with ₹0.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 25 September 2026.
What is Pervasive Commodities Ltd's cash flow?
Pervasive Commodities Ltd consumed ₹37.2 Cr of operating cash in FY26 — cash flowed out rather than in (free cash flow: ₹−37.0 Cr). Reported profit that year was ₹−0.0 Cr, so operating cash ran behind profit. Cash-flow resolution for India is annual. — as of 25 September 2026.
Is Pervasive Commodities Ltd's profit real cash?
No — operating cash was negative over the last 3 fiscal years: Pervasive Commodities Ltd consumed cash while reporting profit. In FY26, operating cash was ₹−37.2 Cr against reported profit of ₹−0.0 Cr. Cash-flow resolution is annual — as of 25 September 2026.
Where is Pervasive Commodities Ltd in its business cycle?
Pervasive Commodities Ltd's FY26 operating margin was 37.2%, against a 10-year band of −112.5%–37.2%: the top of the band — a record year. Record profitability is late-cycle territory: every ratio flatters at the top, and the story leans on margins holding. The latest quarter ran −10.2%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 25 September 2026.
What could break the Pervasive Commodities Ltd story?
Biggest watch item: margins are the best this company has ever printed — every ratio flatters at record profitability, so the whole story leans on margins holding. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 25 September 2026.
Is Pervasive Commodities Ltd a stock worth studying right now?
This is not investment advice. The machine read: Pervasive Commodities Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 25 September 2026.
Not SEBI Registered !! Not Investment advice !!